FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to biotechnology and can be used in medicine. Described is use of a non-natural amatoxin conjugate with an antibody as an anti-tumour or anti-cancer drug with high activity and improved stability in blood plasma.
EFFECT: invention widens the range of agents possessing pronounced cytotoxic activity, and can be used in cancer therapy.
2 cl, 4 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY CONJUGATE WITH NON-NATURAL AMATOXIN | 2018 |
|
RU2798981C2 |
| AMANTINE CONJUGATE WITH ANTIBODY | 2018 |
|
RU2809116C2 |
| AMATHOXINE-ANTIBODY CONJUGATES | 2016 |
|
RU2724328C2 |
| AMATOXIN DERIVATIVES | 2014 |
|
RU2695370C2 |
| NEW METHOD FOR SYNTHESIS OF AMANITINES | 2018 |
|
RU2792210C2 |
| AMATOXIN-CONJUGATES WITH IMPROVED LINKERS | 2011 |
|
RU2601411C2 |
| AMATOXIN CONJUGATES WITH IMPROVED BONDS | 2012 |
|
RU2575854C2 |
| SYNTHESIS OF (S)-6-HYDROXYTRYPTOPHANE AND ITS DERIVATIVES | 2019 |
|
RU2810786C2 |
| LINKER FOR ANTIBODY-DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2792201C2 |
| METHODS OF TREATING CANCER, HAVING HEMIZYGOUS LOSS OF TP53 | 2016 |
|
RU2721953C2 |
